Dermatology

The FDA has approved Eli Lilly and Company's ixekizumab (Taltz) as a treatment for moderate to severe plaque psoriasis.

Ixekizumab (Taltz) approved for moderate-to-severe plaque psoriasis in adults.

Etanercept shows sustained efficacy treating the symptoms of 3 juvenile idiopathic arthritis categories.

Enbrel would be the first systemic drug approved in the United States that treats chronic severe plaque psoriasis in pediatric patients.

The FDA is reviewing Amgen's supplemental biologics license application for the expanded use of etanercept to treat pediatric patients with chronic severe plaque psoriasis.

Toll-like receptor 4 behave differently on psoriasis skin compared with uninvolved skin.

Psoriatic arthritis patients who achieve persistent minimal disease activity more likely to experience long-term improvement with golimumab.

Psoriatic arthritis patients are more likely to develop conditions such as hypertension, diabetes, obesity, and dyslipidemia.

The FDA has approved betamethasone dipropionate spray, 0.05%, as a treatment for mild to moderate plaque psoriasis in patients aged 18 years and older.

Sernivo Spray treats mild-to-moderate plaque psoriasis in patients 18 years of age and up.

Higher risk of serious infection found with adalimumab and infliximab compared with nonmethotrexate and nonbiologic therapies.

Brodalumab is monoclonal antibody that targets the IL-17 receptor.

The FDA is examining a biologics license application for brodalumab injection 210 mg as a treatment for moderate to severe plaque psoriasis.

Cutaneous psoriasis used to describe an individual who suffered from the disease for at least a decade.

Patients with inflammatory rheumatic diseases may not need more frequent vaccinations.

Cosentyx was previously approved for the treatment of moderate-to-severe plaque psoriasis.

Cosentyx was previously approved for the treatment of moderate-to-severe plaque psoriasis.

Researchers compare efficacy and side effects of different psoriatic arthritis treatment options.

Researchers compare efficacy and side effects of different psoriatic arthritis treatment options.

Research compares multidimensional approaches with uni-dimensional interventions.

Researchers evaluate association between psoriasis and cancer.

Prescription drugs costs for patients with psoriatic arthritis tended to be higher than comparable costs for ankylosing spondylitis.

Balanced approach needed to better discriminate between high and low disease activity.

Patients who received golimumab and methotrexate reported larger improvements than monotherapy patients.

Novel oral treatment for moderate-to-severe plaque psoriasis deemed an effective option.

Significant weight loss found to reduce disease burden in psoriatic arthritis patients.

Ixekizumab found to improve skin clearance of plaque psoriasis and reduced disability when performing certain physical functions.

Cosentyx found to maintain improvements in joint and skin disease, physical function, and quality of life in PsA patients.

Combination of risk factors and PsA disease activity found increase dangers of cardiovascular disease.

Heritability plays more of a factor in pediatric-onset autoimmune diseases than in adult diseases.